The Management of Scabies in the 21st Century: Past, Advances and Potentials
DOI:
https://doi.org/10.2340/00015555-3468Keywords:
scabies, Sarcoptes scabiei, neglected tropical disease, ivermectin, permethrin, moxidectin, acaricide discovery and development, ovicidalAbstract
Scabies is one of the most common skin diseases worldwide, affecting 150?200 million people yearly. Scabies affects young children in particular, and has the greatest impact in poor overcrowded living conditions. The burden of the disease is now well characterized, including group A Streptococcus and Staphylococcus aureus bacterial superinfections, with reports of nephritis, acute rheumatic fever, or fatal invasive sepsis secondary to scabies. Management of scabies remains largely suboptimal from diagnosis to treatment, and progress in the development of new therapeutic measures leading to cure is urgently needed. This review gives an overview of the current limitations in the management of scabies, an update on recent advances, and outlines prospects for potential improvements.Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Charlotte Bernigaud, Katja Fischer, Olivier Chosidow
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.